What You Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Assessment

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about gastroparesis. This condition, where the stomach empties too slowly, has been reported in association with GLP-1 receptor agonists. The long-standing tradition of translating complex medical research into accessible information helps us understand these emerging concerns. This guide explains the symptoms, FDA warnings, and what current science says about the connection.

Understanding Ozempic and Its Mechanism of Action

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Among the most serious potential complications is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical data from placebo-controlled trials demonstrate a significantly higher incidence of gastrointestinal adverse reactions in patients receiving Ozempic compared to placebo. In the pooled analysis, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Nausea was reported in 6.1% of placebo patients versus 15.8% and 20.3% for Ozempic 0.5 mg and 1 mg, respectively. Vomiting occurred in 2.3% of placebo patients compared to 5.0% and 9.2% for the two Ozempic doses. Diarrhea was also more common, with rates of 1.9% in placebo versus 8.5% and 8.8% for Ozempic 0.5 mg and 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms are consistent with the clinical presentation of gastroparesis, which includes nausea, vomiting, postprandial fullness, and abdominal discomfort.

The Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves its effect on gastric motility. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended to improve glycemic control but can become pathological when it leads to sustained gastroparesis. Postmarketing reports have highlighted the risk of retained gastric contents, even after adherence to preoperative fasting recommendations, in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for clinically significant gastroparesis that can persist beyond the acute phase of treatment. The adequacy of warnings regarding Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a specific adverse reaction. Instead, it describes symptoms such as nausea, vomiting, and diarrhea, which are common in gastroparesis but may not alert patients and healthcare providers to the risk of delayed gastric emptying as a distinct condition. The label also notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not provide specific guidance on monitoring for gastroparesis. This gap in labeling may affect the ability of patients to recognize early signs of gastroparesis and seek timely medical intervention.

Statute of Limitations for Ozempic Lawsuits in Massachusetts

For patients in Massachusetts who have developed gastroparesis after using Ozempic, attorney-related considerations are important. The statute of limitations for product liability claims in Massachusetts is generally three years from the date of injury or from when the injury reasonably should have been discovered. Given that gastroparesis symptoms may develop gradually during Ozempic treatment, the timeline between exposure and documented harm is crucial. Patients who experienced gastrointestinal symptoms during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), should document the onset of symptoms and any medical evaluations. The discontinuation rates due to gastrointestinal adverse reactions were higher in Ozempic-treated patients (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), indicating that some patients experienced severe enough symptoms to stop treatment. This may serve as a marker for potential gastroparesis. In summary, the evidence supports a plausible link between Ozempic use and gastroparesis through its mechanism of delayed gastric emptying. The clinical trial data show elevated rates of gastrointestinal symptoms consistent with gastroparesis, and postmarketing reports highlight risks of retained gastric contents. The adequacy of warnings may be insufficient to fully inform patients of this specific risk. Patients in Massachusetts should be aware of the statute of limitations and the importance of documenting the timeline from Ozempic exposure to gastroparesis diagnosis. Legal consultation is recommended for those affected.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic lawsuit in Massachusetts?

In Massachusetts, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury reasonably should have been discovered. For Ozempic-related gastroparesis, it is crucial to document the onset of symptoms and medical evaluations to establish the timeline.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) delays gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This intended effect can become pathological, leading to sustained gastroparesis. Clinical trials show significantly higher rates of gastrointestinal symptoms like nausea and vomiting in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.